Skip to main content

Market Overview

Elbit Says FDA Approves INSIGHTEC's Exablate Neuro For Essential Tremor Treatment

Share:

Elbit Imaging Ltd. (NASDAQ: EMITF) revealed that today that it was informed by INSIGHTEC Ltd. that the FDA has given its approval for its Exablate Neuro system for a non-invasive treatment of essential tremor (ET) in patients, who have not responded to medication.

Elbit Imaging said that Exablate Neuro utilized concentrated ultrasound waves to exactly target and ablate tissue deep within the brain with no incisions or implants. The company added that the treatment was done under Magnetic Resonance Imaging (MRI) guidance for real time treatment monitoring.

The company indicated that essential tremor was the most common movement disorder, and affects over 5 million people in the United States alone apart millions around the world. The company added that hand tremor was the most common symptom. However, tremors could affect the head, arms, voice, legs, and torso.

Elibit statement said, "This approval by the FDA was based on clinical data from a randomized, double-blind, multi-center clinical study designed to evaluate the safety and efficacy of non-invasive thalamotomy with MRI-guided Focused Ultrasound. A total of 76 patients were enrolled in the study and randomly assigned to receive the Exablate treatment (56 patients) or the sham procedure (20 patients), the exact same procedure but without any ultrasound energy."

Following this, the stock traded 5.12 percent up on Tuesday.

 

Related Articles (EMITF)

View Comments and Join the Discussion!

Posted-In: Biotech News FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com